This clinical trial is focused on studying the effects of a treatment for Early Alzheimer’s Disease, a condition that affects memory and thinking skills. The treatment being tested is called XPro1595, which is a type of protein designed to help with inflammation in the brain. Inflammation is a response by the body’s immune system that can sometimes cause harm if it happens in the brain. The study will compare the effects of XPro1595 with a placebo, which looks like the treatment but does not contain the active ingredient.

The purpose of the study is to see how well XPro1595 works in improving cognitive performance, which includes memory and other mental abilities, in people with early Alzheimer’s Disease. Participants in the study will receive either the XPro1595 treatment or a placebo through an injection. The study will last for about 33 weeks, during which participants will have regular assessments to monitor changes in their cognitive abilities.

Throughout the study, participants will undergo various tests to measure their memory and thinking skills. These tests will help researchers understand if XPro1595 can make a difference in managing symptoms of early Alzheimer’s Disease. The study aims to provide valuable information on whether this new treatment can help improve the quality of life for those affected by this condition.